References:

MSAA's booklets: Multiple Sclerosis, The Process and Medical Treatments, 4th edition, 2002, and Multiple Sclerosis, Managing Symptoms, 3rd edition, 2002.

Burks J.S., Johnson K.P., Multiple Sclerosis — Diagnosis, Medical Management, and Rehabilitation, Demos Medical Publishing, New York, 2000.

Goodin D.S., Frohman E.M., Garmany G.P., et al., Disease modifying therapies in multiple sclerosis: Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines, Neurology, 2002, 58, pp. 169-178.

Jacobs, L., et al., Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis, CHAMPS Study Group, New England Journal of Medicine, Sept. 28, 2000, 343 (13), pp. 898-904.

Johnson K.P., Brooks B.R., Ford C.C., et al., Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for six years, Multiple Sclerosis (2000), 6, pp. 255-266.

Kalb R.C., Multiple Sclerosis, The Questions You Have — The Answers You Need, second edition, Demos Medical Publishing, New York, 2000.

Kappos L., Polman C., Pozzilli C., Final analysis of the European multicenter trial of IFN beta-1b in secondary progressive MS, Neurology, Dec. 2001, 57 (11), pp. 1969-75.

Mikol DD., Treat early, but treat hard: interferon-beta dose makes a difference, Journal of Neurophthalmology, December 2001, 21 (4), 237-9.

Noseworthy J.H., Lucchinetti C., Rodriguez M., et al., Multiple sclerosis, The New England Journal of Medicine, Sep. 28, 2000, pp. 938-952.

Polman C.H., Thompson A.J., Murray T.J., McDonald W. I., Multiple Sclerosis, The Guide to Treatment and Management, fifth edition, Demos Medical Publishing, New York, 2001.

PRISMS-4, Long-term efficacy of interferon-beta-1a in relapsing MS, Neurology, June 26, 2001, 56 (12), pp. 1628-36.

Rolak L.A., Multiple sclerosis treatment 2001, Neurologic Clinics, Volume 19 Number 1 Feb. 2001, pp 107-118.

Van den Noort S., Holland N.J., Multiple Sclerosis in Clinical Practice, Demos Medical Publishing, New York, 1999.

The Multiple Sclerosis Association of America (MSAA) is a national nonprofit organization dedicated to enriching the quality of life for individuals with multiple sclerosis. MSAA provides ongoing support and direct services to individuals with MS and the people close to them. MSAA also serves to promote greater understanding of the needs and challenges of those with MS.

MSAA provides a variety of programs and services, including:

• Toll-free Helpline (800) 532-7667
• Support groups
• Equipment Distribution Program
• Home Modification Program
• MRI Diagnostic Fund
• MRI Institute (follow-up MRI assistance and advocacy)
• Educational literature
• Quarterly magazine, The Motivator
• Lending Library
• Cooling Equipment Distribution Program (to provide relief for heat-sensitive individuals)
• Barrier-free Housing Program
• Networking Program (linking clients through letters and email)
• Informative regional events (helping to promote awareness)

If you would like additional information about multiple sclerosis, the Multiple Sclerosis Association of America, or its programs and services, please call (800) 532-7667. You may also visit MSAA's website at www.msaa.com .

MSAA programs and services listed above are supported by individual and corporate contributions. If you would like to offer support to MSAA, please call (800) 532-7667, extension 159 or visit MSAA's website at www.msaa.com and select "how to give." Your donations are greatly appreciated.

Back: Looking Ahead |Index